WNK2 and neoplasm: Itaconate promotes tumor growth via oxidative phosphorylation-driven ROS generation in peritoneal tissue-resident macrophages and concomitant ROS-mediated mitogen-activated protein kinases (MAPKs) activation in tumor cells (79).